Takeda Reports Positive Results from Phase 2/3 Trial of TAK-881 for Primary Immunodeficiency
Takeda has announced positive topline results from its Phase 2/3 clinical trial of TAK-881 in patients with Primary Immunodeficiency Disease (PID). The trial demonstrated pharmacokinetic comparability between TAK-881 and the established HYQVIA treatment, with TAK-881 showing reduced infusion volume and duration. The investigational therapy achieved comparable safety, efficacy, and tolerability profiles, offering potential advantages such as fewer injection sites and shorter infusion times. Takeda plans to submit applications for regulatory approval in the U.S., EU, and Japan in fiscal year 2026. 
